Key insights
- Becton Dickinson (BDX) shares rose after Q2 earnings and revenue beat estimates, driven by strong U.S. revenue growth. The company raised its full-year EPS guidance, exceeding consensus estimates, while reiterating revenue growth guidance. This positive performance in a major healthcare company suggests continued strength in the medical device sector and contributes to overall market optimism.
Investing.com -- Becton Dickinson shares climbed after the medical device maker beat second-quarter profit and revenue estimates and raised its full-year earnings guidance.
Becton also announced it has appointed Vitor Roque as executive vice president and chief financial officer, effective May 7. Roque served as interim CFO since December 2025.
The stock was up 3.3% in premarket trading by 06:41 ET.
The company reported Q2 earnings per share of $2.90, topping analyst estimates of $2.78, on revenue of $4.7 billion, up 2.6% on a currency-neutral basis and just ahead of the $4.67 billion consensus.
Regionally, U.S. revenue grew 5.1% on a currency-neutral basis to $2.91 billion, while international revenues slipped 1.4% to $1.8 billion.
"We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD. "Execution was broad-based, with more than 90% of the business delivering mid‑single‑digit growth, strong performance from our growth platforms and ongoing margin momentum from BD Excellence."
Looking forward, Becton raised its full-year EPS outlook to $12.52–$12.72 from a prior range of $12.35–$12.65, straddling the consensus estimate of $12.48. The company reiterated its revenue guidance for low-single-digit growth.